Thyme Honey for Management of Oral Lichen Planus
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: thyme honey, Triamcinolone Acetonide.
- Who it may be relevant to
- Registry conditions: Oral Lichen Planus. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Thyme Honey for Management of Oral Lichen Planus: A Non- Inferiority Controlled Randomized Clinical Trial
Overview
the study aimed to assess the effect of topical application of thyme honey in comparison to 0.1% triamcinolone acetonide oral paste on the relief of pain and clinical improvement in patients with OLP
Interventions
- Dietary supplement thyme honey
Topical application on the oral mucosa - Drug Triamcinolone Acetonide
Topical application on the oral mucosa
Primary outcome measures
- VAS score assessement [Time frame: 1 month]
Secondary outcome measures (1)
- measurement of salivary level of miRna155 [Time frame: 1 month]
Eligibility criteria
Inclusion Criteria:• Patients clinically and histopathologically (if required) diagnosed as suffering from OLP.
- Patients free from any visible oral lesions other than OLP.
- Patients who agreed to take supplied medications.
- Patients who agreed for the biopsy (when required).
Exclusion Criteria:• •Patients suffering from any systemic disease.
- Treatment with any systemic treatment such as systemic steroids, other immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks.
- Treatment with any oral topical medications for at least four weeks prior to the study.
- Pregnant and lactating women.
- In addition, no consideration was given to patients with a history of hypersensitivity to honey.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- The British university in Egypt — Cairo
Identifiers
NCT: NCT06810752 · 24-092